This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
10 Feb 2011

Philogen Prepares First European Biotech IPO in 2011

Swiss-Italian biotech group Philogen plans to debut on the Milan stock exchange later this month.

Philogen is making a bid to become the first European drug developer to go public this year. The Swiss-Italian biotech plans to go public on the Milan market, where it hopes to raise up to €65.3 million. Philogen claims to be profitable. 

 

The company says it has six anti-cancer antibody derivatives and an antibody-derivative for the treatment of rheumatoid arthritis in clinical studies. Two registrational studies--one in Phase III and one in Phase II--are in the planning stage.

Related News